A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment

References

• Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467-72; PMID:21430775; http://dx.doi.org/10.1038/nature09837
   PubMed Web of Science ®Google Scholar
• Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 2009; 113:2290-7; PMID:19050310; http://dx.doi.org/10.1182/blood-2007-05-089193
   PubMed Web of Science ®Google Scholar
• Alagpulinsa DA, Ayyadevara S, Shmookler Reis RJ. A small molecule inhibitor of RAD51 reduces homologous recombination and sensitizes multiple myeloma cells to doxorubicin. Front Oncol 2014 ( In press); 4:289; PMID:25401086
   PubMedGoogle Scholar
• San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 2008; 77:229-57; PMID:18275380; http://dx.doi.org/10.1146/annurev.biochem.77.061306.125255
   PubMed Web of Science ®Google Scholar
• Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of RAD51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998; 26:2859-64; PMID:9611228; http://dx.doi.org/10.1093/nar/26.12.2859
   PubMed Web of Science ®Google Scholar
• Yang Z, Waldman AS, Wyatt MD. Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol 2012; 83:741-6; PMID:22222428; http://dx.doi.org/10.1016/j.bcp.2011.12.022
   PubMed Web of Science ®Google Scholar
• Kassambara A, Gourzones-Dmitriev C, Sahota S, Reme T, Moreaux J, Goldschmidt H, Constantinou A, Pasero P, Hose D, Klein B. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. Oncotarget 2014; 5(9):2487-98; PMID:24809299
   PubMedGoogle Scholar
• Lawley PD, Brookes P. Molecular mechanism of the cytotoxic action of difunctional alkylating agents and of resistance to this action. Nature 1965; 206:480-3; PMID:5319105; http://dx.doi.org/10.1038/206480a0
   PubMed Web of Science ®Google Scholar
• Long DT, Raschle M, Joukov V, Walter JC. Mechanism of RAD51-dependent DNA interstrand cross-link repair. Science 2011; 333:84-7; PMID:21719678; http://dx.doi.org/10.1126/science.1204258
   PubMed Web of Science ®Google Scholar
• Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002; 100:224-9; PMID:12070031; http://dx.doi.org/10.1182/blood.V100.1.224
   PubMed Web of Science ®Google Scholar
• Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005; 106:698-705; PMID:15802532; http://dx.doi.org/10.1182/blood-2004-11-4286
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Yang YG, Pierce AJ, Taniguchi T, Digweed M, D'Andrea AD, Wang ZQ, Jasin M. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A 2005; 102:1110-5; PMID:15650050; http://dx.doi.org/10.1073/pnas.0407796102
   PubMedGoogle Scholar
• Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, Duggan P, Tassone P, Mansoor A, Stewart DA, et al. Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors. Blood 2011; 118:6368-79; PMID:21917757; http://dx.doi.org/10.1182/blood-2011-06-363911
   PubMed Web of Science ®Google Scholar
• Wang ZM, Chen ZP, Xu ZY, Christodoulopoulos G, Bello V, Mohr G, Aloyz R, Panasci LC. In vitro evidence for homologous recombinational repair in resistance to melphalan. J Natl Cancer Inst 2001; 93:1473-8; PMID:11584063; http://dx.doi.org/10.1093/jnci/93.19.1473
   PubMed Web of Science ®Google Scholar
• Xia SJ, Shammas MA, Shmookler Reis RJ. Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cell Biol 1997; 17:7151-8; PMID:9372947
   PubMed Web of Science ®Google Scholar
• Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of RAD51 recombination protein in tumor cells. Cancer Res 2002; 62:219-25; PMID:11782381
   PubMed Web of Science ®Google Scholar
• Wiegmans AP, Al-Ejeh F, Chee N, Yap PY, Gorski JJ, Da Silva L, Bolderson E, Chenevix-Trench G, Anderson R, Simpson PT, et al. RAD51 supports triple negative breast cancer metastasis. Oncotarget 2014; 5(10):3261-72; PMID:24811120
   PubMedGoogle Scholar
• Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, Stark JM, Kozikowski AP, Bishop DK, Connell PP. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res 2012; 40:7347-57; PMID:22573178; http://dx.doi.org/10.1093/nar/gks353
   PubMed Web of Science ®Google Scholar
• Normand A, Riviere E, Renodon-Corniere A. Identification and characterization of human RAD51 inhibitors by screening of an existing drug library. Biochem Pharmacol 2014; 91:293-300; PMID:25124703; http://dx.doi.org/10.1016/j.bcp.2014.07.033
   PubMed Web of Science ®Google Scholar
• Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. RAD51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005; 7:1044-52; PMID:15756713; http://dx.doi.org/10.1002/jgm.753
   PubMed Web of Science ®Google Scholar
• Sak A, Stueben G, Groneberg M, Bocker W, Stuschke M. Targeting of RAD51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br J Cancer 2005; 92:1089-97; PMID:15785736; http://dx.doi.org/10.1038/sj.bjc.6602457
   PubMed Web of Science ®Google Scholar
• Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001; 29:1534-8; PMID:11266555; http://dx.doi.org/10.1093/nar/29.7.1534
   PubMed Web of Science ®Google Scholar
• Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254:1497-500; PMID:1962210; http://dx.doi.org/10.1126/science.1962210
   PubMed Web of Science ®Google Scholar
• Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim SK, Norden B, Nielsen PE. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 1993; 365:566-8; PMID:7692304; http://dx.doi.org/10.1038/365566a0
   PubMed Web of Science ®Google Scholar
• Demidov VV, Potaman VN, Frank-Kamenetskii MD, Egholm M, Buchard O, Sonnichsen SH, Nielsen PE. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol 1994; 48:1310-3; PMID:7945427; http://dx.doi.org/10.1016/0006-2952(94)90171-6
   PubMed Web of Science ®Google Scholar
• Kaihatsu K, Janowski BA, Corey DR. Recognition of chromosomal DNA by PNAs. Chem Biol 2004; 11:749-58; PMID:15217608; http://dx.doi.org/10.1016/j.chembiol.2003.09.014
   PubMed Web of Science ®Google Scholar
• Belotserkovskii BP, Hanawalt PC. PNA binding to the non-template DNA strand interferes with transcription, suggesting a blockage mechanism mediated by R-loop formation. Mol Carcinog 2014; 30:22209
   Google Scholar
• Janowski BA, Kaihatsu K, Huffman KE, Schwartz JC, Ram R, Hardy D, Mendelson CR, Corey DR. Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids. Nat Chem Biol 2005; 1:210-5; PMID:16408037; http://dx.doi.org/10.1038/nchembio724
   PubMed Web of Science ®Google Scholar
• Holstege FC, Fiedler U, Timmers HT. Three transitions in the RNA polymerase II transcription complex during initiation. EMBO J 1997; 16:7468-80; PMID:9405375; http://dx.doi.org/10.1093/emboj/16.24.7468
   PubMed Web of Science ®Google Scholar
• Hine CM, Seluanov A, Gorbunova V. Use of the RAD51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci U S A 2008; 105:20810-5; PMID:19106292; http://dx.doi.org/10.1073/pnas.0807990106
   PubMedGoogle Scholar
• Cutrona G, Carpaneto EM, Ulivi M, Roncella S, Landt O, Ferrarini M, Boffa LC. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat Biotechnol 2000; 18:300-3; PMID:10700145; http://dx.doi.org/10.1038/73745
   PubMed Web of Science ®Google Scholar
• Cogoi S, Codognotto A, Rapozzi V, Meeuwenoord N, van der Marel G, Xodo LE. Transcription inhibition of oncogenic KRAS by a mutation-selective peptide nucleic acid conjugated to the PKKKRKV nuclear localization signal peptide. Biochemistry 2005; 44:10510-9; PMID:16060660; http://dx.doi.org/10.1021/bi0505215
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8; http://dx.doi.org/10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004; 18:1891-7; PMID:15385929; http://dx.doi.org/10.1038/sj.leu.2403513
   PubMed Web of Science ®Google Scholar
• Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol 2007; 138:802-11; PMID:17760811; http://dx.doi.org/10.1111/j.1365-2141.2007.06742.x
   PubMed Web of Science ®Google Scholar
• Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009; 84:6-14; PMID:18980173; http://dx.doi.org/10.1002/ajh.21310
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002; 100:2414-20; PMID:12239151; http://dx.doi.org/10.1182/blood-2002-01-0278
   PubMed Web of Science ®Google Scholar
• Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R. XRCC3 induces cisplatin resistance by stimulation of RAD51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 2005; 314:495-505; PMID:15843498; http://dx.doi.org/10.1124/jpet.105.084053
   PubMed Web of Science ®Google Scholar
• Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273:5858-68; PMID:9488723; http://dx.doi.org/10.1074/jbc.273.10.5858
   PubMed Web of Science ®Google Scholar
• Raderschall E, Golub EI, Haaf T. Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage. Proc Natl Acad Sci U S A 1999; 96:1921-6; PMID:10051570; http://dx.doi.org/10.1073/pnas.96.5.1921
   PubMedGoogle Scholar
• Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF. Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia 2011; 25:1344-53; PMID:21566653; http://dx.doi.org/10.1038/leu.2011.94
   PubMed Web of Science ®Google Scholar
• Raderschall E, Bazarov A, Cao J, Lurz R, Smith A, Mann W, Ropers HH, Sedivy JM, Golub EI, Fritz E, et al. Formation of higher-order nuclear RAD51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis. J Cell Sci 2002; 115:153-64; PMID:11801733
   PubMed Web of Science ®Google Scholar
• Resnick MA, Martin P. The repair of double-strand breaks in the nuclear DNA of Saccharomyces cerevisiae and its genetic control. Mol Gen Genet 1976; 143:119-29; PMID:765749; http://dx.doi.org/10.1007/BF00266917
   PubMedGoogle Scholar
• Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009; 69:9367-75; PMID:19934314; http://dx.doi.org/10.1158/0008-5472.CAN-09-2616
   PubMed Web of Science ®Google Scholar
• Carvalho JF, Kanaar R. Targeting homologous recombination-mediated DNA repair in cancer. Expert Opin Ther Targets 2014; 18(4):427-58; PMID:24491188; http://dx.doi.org/10.1517/14728222.2014.882900
   PubMed Web of Science ®Google Scholar
• Hine CM, Li H, Xie L, Mao Z, Seluanov A, Gorbunova V. Regulation of RAD51 promoter. Cell Cycle 2014; 13:2038-45; PMID:24781030; http://dx.doi.org/10.4161/cc.29016
   PubMed Web of Science ®Google Scholar
• Hine CM, Seluanov A, Gorbunova V. RAD51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer. Mol Ther 2012; 20:347-55; PMID:22008909; http://dx.doi.org/10.1038/mt.2011.215
   PubMed Web of Science ®Google Scholar
• Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, Kiltie AE. Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res 2013; 73:1611-20; PMID:23302228; http://dx.doi.org/10.1158/0008-5472.CAN-12-1170
   PubMed Web of Science ®Google Scholar
• Yang C, Betti C, Singh S, Toor A, Vaughan A. Impaired NHEJ function in multiple myeloma. Mutat Res 2009; 660:66-73; PMID:19028508; http://dx.doi.org/10.1016/j.mrfmmm.2008.10.019
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004; 6:439-44; PMID:15542427; http://dx.doi.org/10.1016/j.ccr.2004.10.020
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104:607-18; PMID:15090448; http://dx.doi.org/10.1182/blood-2004-01-0037
   PubMed Web of Science ®Google Scholar